Waltham, Mass., USA - July 16, 2015, Waltham, Mass., USA - Histogenics Corporation, a regenerative medicine company, announced the appointment of Gloria Matthews as its chief medical officer.
Article continues below
Dr. Matthews brings more than 20 years of global research, development and surgical experience in orthopedics and cartilage repair to Histogenics.
She is an accomplished scientist, educator, guest speaker and surgeon with broad ranging expertise in orthopedic and rheumatologic diseases, among other therapeutic areas, and has significant functional experience in cellular and gene therapy, biomaterials and growth factors.
Prior to Histogenics, Dr. Matthews most recently served as Senior Director and Global Head of Bone and Joint Disease Research and Development at Genzyme, a Sanofi company.
During her tenure at Genzyme, Dr. Matthews was involved in clinical and preclinical development and/or post-market support of cell, gene, growth factor, small molecule, and biomaterial based products in the orthopedic and rheumatologic space, including Carticel, MACI, Synvisc, Synvisc One, and an early clinical development stage Trk inhibitor for osteoarthritis.
Her active research areas include cell and molecular biology of osteoarthritis and cartilage repair as well as orthopedic imaging. Dr. Matthews sits on the Board of Directors for the Orthopaedic Research Society for which she chairs the Executive Finance Committee as Treasurer.
She chairs the Musculoskeletal Committee of the American Society for Gene and Cell Therapy and also serves on the NIH SBIR Scientific Review Group/Grant Review Committee (study section), the Strategic Alliance Committee of the Osteoarthritis Research Society International, the fNIH Osteoarthritis Biomarkers Working Group, and as a reviewer for the Osteoarthritis Initiative Bioresource Allocation Committee.
Dr. Matthews has also established several high-profile collaborations in medicine, academia and industry, and is a published inventor and researcher. ■